Immunitybio is trading at $10.40, up +4.99%, during the October 9, 2026 session, with no clear company-specific catalyst identified for the gain.
- Immunitybio announced an October 15–16 Piper Sandler symposium appearance on October 8; available coverage does not connect it to the share move.
- The biotech sector is down while Immunitybio rises. Broad-market moves are modest and do not establish a cause.